Russian Parliament to take tough stand over counterfeit drugs

29 November 2013
medical_legal_law_big

The Russian Parliament (State Duma) plans to significantly tighten responsibility for the production and distribution of counterfeit drugs, through the adoption of a special bill, which is expected to take place by the end of the current year.

Assuming adoption of the legislation, it is planned that criminal responsibility for the production of drugs and medical products without a license will result in at least five to eight years of imprisonment with a fine of up to 2 million roubles ($70,000). In the most severe cases, which resulted in serious consequences, 12 years of imprisonment and a fine in the amount up to 5 million roubles could be imposed on those responsible. This will be significantly strengthen the current norms in the Russian Criminal Code.

At present the problem of fake drugs is very pressing in Russia. According to official data of the Russian Ministry of Internal Affairs, for the first half of this year the Russian law enforcement agencies detected up to191 series of 122 trade names of fake drugs, as well as 50 series of counterfeit pharmaceutical substances

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical